This is an intent-to-treat, split-plot design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.

Start Date15 Jan 2025

Sponsor / Collaborator

VA Office of Research and Development

NCT06686043 / RecruitingPhase 2IIT

A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are:
Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone.
Participants will:
Receive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation.
Have blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit.
Take a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.

Start Date23 Aug 2024

Sponsor / Collaborator

Baylor College of Medicine

[+2]

RBR-3j6jwg3 / RecruitingPhase 3IIT

Randomized clinical trial to evaluate the efficacy and safety of Intralesional Meglumine Antimoniate associated with topical Imiquimod in the treatment of Cutaneous Leishmaniasis

Start Date20 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Imiquimod

100 Translational Medicine associated with Imiquimod

100 Patents (Medical) associated with Imiquimod

4,397

Literatures (Medical) associated with Imiquimod

01 Apr 2025·BIOMATERIALS

On-demand reprogramming of immunosuppressive microenvironment in tumor tissue via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immunotherapy using engineered gold nanoparticles for malignant tumor treatment

Article

Author: Liu, Tao ; Zhu, Zeren ; Chen, Xin ; Tang, Xiaoyu ; Mu, Wenyun ; Weng, Lin ; Zhang, Yanmin ; Liu, Jie ; Cheng, Yumeng ; Tang, Wenjun ; Zhu, Man ; Chen, Li

The frequent immune escape of tumor cells and fluctuating therapeutic efficiency vary with each individual are two critical issues for immunotherapy against malignant tumor. Herein, we fabricated an intelligent core-shell nanoparticle (SNAs@CCM_R) to significantly inhibit the PD-1/PD-L1 mediated immune escape by on-demand regulation of various oncogenic microRNAs and perform RNAs dependent photothermal-immunotherapy to achieve precise and efficient treatment meeting the individual requirements of specific patients by in situ generation of customized tumor-associated antigens. The SNAs@CCM_R consisted of antisense oligonucleotides grafted gold nanoparticles (SNAs) as core and TLR7 agonist imiquimod (R837) functionalized cancer cell membrane (CCM) as shell, in which the acid-labile Schiff base bond was used to connect the R837 and CCM. During therapy, the acid environment of tumor tissue cleaved the Schiff base to generate free R837 and SNAs@CCM. The SNAs@CCM further entered tumor cells via CCM mediated internalization, and then specifically hybridized with over-expressed miR-130a and miR-21, resulting in effective inhibition of the migration and PD-L1 expression of tumor cells to avoid their immune escape. Meanwhile, the RNAs capture also caused significant aggregation of SNAs, which immediately generated photothermal agents within tumor cells to perform highly selective photothermal therapy under NIR irradiation. These chain processes not only damaged the primary tumor, but also produced plenty of tumor-associated antigens, which matured the surrounding dendritic cells (DCs) and activated anti-tumor T cells along with the released R837, resulting in the enhanced immunotherapy with suppressive immune escape. Both in vivo and in vitro experiments demonstrated that our nanoparticles were able to inhibit primary tumor and its metastasis via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immune activations, which provided a promising strategy to reprogram the immunosuppressive microenvironment in tumor tissue for better malignant tumor therapy.

01 Mar 2025·Journal of Stomatology Oral and Maxillofacial Surgery

Comparative evaluations of different surgical and non-surgical treatment methods for early invasive and micro invasive squamous cell carcinoma in the oral and maxillofacial regions: A systematic review

Article

Author: Yousefi-Koma, Hannaneh ; Yousefi-Koma, Amir-Ali ; Mashhadiabbas, Fatemeh ; Baniameri, Sahar

OBJECTIVES:

The pathogenesis and progressive behavior of head, neck, oral and maxillofacial (HNOMF) squamous cell carcinoma (SCC) has been suggested to be a multistep and multifactorial procedure that necessitates epithelial hyperplasia, epithelial dysplasia, micro invasive squamous cell carcinoma (MISCC) and early invasive squamous cell carcinoma (EISCC); EISCC and MISCC might have a completely different behavior and development process. There are only a limited number of reported HNOMF cases of EISCC or MISCC. There are still no guidelines for the treatment of EISCC and MISCC lesions in the HNOMF regions.

MATERIAL AND METHODS:

This systematic review was conducted to gather all surgical and non-surgical treatments for EISCC and MISCC lesions in the HNOMF. The study question according to the PICO format was as followed: clinical and histopathological results (O) of all types of treatments (I) for patients with EISCC and MISCC lesions in HNOMF (P) compared to untreated lesions (C). Medline, Scopus, and Google Scholar were searched and the search was limited to English-language.

RESULTS:

Eight clinical human studies were included. Photodynamic therapy (PDT) after topical application of methyl aminolevulinate (MAL-PDT) and topical Imiquimod 5 % cream both had remarkable outcomes.

CONCLUSIONS:

However, due to the very limited number of studies conducted on the treatment methods of MISCC and EISCC in the HNOMF regions, further studies are necessary to provide reliability for non-surgical treatment methods.

01 Feb 2025·JOURNAL OF ETHNOPHARMACOLOGY

Stilbene-enriched extract from the leaves of Cajanus cajan attenuates psoriasis in imiquimod-induced psoriatic mice by targeting aryl hydrocarbon receptor and chemokines

Article

Author: Wu, Yao-Dan ; Qiu, Si-Lin ; Yao, Li-Yuan ; Zhu, Bao-Jun ; Zhao, Li-Yun ; Qiu, Sheng-Xiang ; Kang, Ming

ETHNOPHARMACOLOGICAL RELEVANCE:

The leaves of Cajanus cajan (L.) Millsp., an Asian traditional folkloric medicine, have been used to treat inflammatory conditions since ancient times. In Southern China, these leaves have been employed to alleviate the symptoms associated with various skin diseases. However, the therapeutic effects and the underlying mechanisms of Cajanus cajan leaves in the treatment of psoriasis remain poorly understood.

AIM OF THE STUDY:

This study aims to investigate the efficacy of stilbene-enriched extract from C. cajan leaves (termed as "EXT") in treating imiquimod (IMQ)-induced psoriatic mice and to elucidate its possible underlying mechanism in psoriasis treatment.

MATERIALS AND METHODS:

The coumpounds of EXT was analyzed through a UPLC-MS system, the MS survey scan was conducted across the mass range of m/z 100-1000 Da. The activation of aryl hydrocarbon receptor (AhR), a potential therapeutic target, by EXT in HaCaT cells was assessed using RT-qPCR and immunofluorescence. Subsequently, EXT was administrated to IMQ-induced psoriatic mice once daily for 10 days. The efficacy of EXT in treating psoriasis was evaluated through pathological analysis including change of weight, PASI score, Baker score, epidermal thickness, and H&E staining of lesion skin. Additionally, transcriptomic analysis of lesion skins was conducted to identify the potential therapeutic targets and possible mechanisms of EXT in psoriasis treatment.

RESULTS:

It was identified that the primary stilbenes present in EXT were 3.10% pinosylvin monomethyl ether (PME), 12.32 % cajaninstilbene (CSA), 4.54 % ongistylin A (LGA) and 2.43 % longistylin C (LGC). In cellular tests, the addition of 2.5 μg/mL EXT to HaCaT cells enhanced the expression of AhR and its nuclear translocation. In vivo tests of EXT in IMQ-induced psoriasis mouse model, 50 mg 1.0 % EXT reduced PASI and Baker score of lesion skin to 2.67 and 4.5, respectively. In addition, the epidermis thickness of lesion skin induced by IMQ returned to normal following the application of 50 mg 1.0 % EXT in psoriatic mice. Transcriptomic profiling revealed significant downregulation of numerous chemokines (Ccl2, Ccl20, and Cxc5, etc.), pro-inflammatory cytokines (Il17a, Il19, Il22, and Il23, etc.), and genes associated with keratinocyte differentiation (Lce and Sprr family genes). Conversely, AhR and genes of the cytochrome P450 family were activated.

CONCLUSIONS:

This study is the first to demonstrate that the ethyl acetate (EtOAc) extract enriched with stilbenes from Cajanus cajan leaves (EXT) effectively alleviates symptoms in IMQ-induced psoriatic mice. The mechanism involves the activation of the aryl hydrocarbon receptor (AhR) and a subsequent reduction in the production of various inflammatory chemokines and cytokines. These findings suggest that EXT holds significant potential as a plant-derived therapeutic agent for the treatment of psoriasis.

News (Medical) associated with Imiquimod

02 Jul 2024

·www.globenewswire.com

Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that George Warren, Ph.D., Principal Scientist at Artelo, Myles Osborn, Medicinal Chemist at Artelo, and Matthew Jones, Ph.D. candidate from the Laviolette laboratory at the University of Western Ontario, Canada, each presented results from research studies demonstrating the broad therapeutic potential of Fatty Acid Binding Protein 5 (FABP5) inhibition at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium. The ICRS Symposium is being held June 30 – July 5, 2024 in Salamanca, Spain. Targeting FABP5, a promising new approach to treat cancer, was featured in the presentation “Efficacy of ART26.12, a Novel Fatty Acid Binding Protein 5 Inhibitor, in an Orthotopic HCT-116-LUC Human Colon Cancer Model.” Myles Osborn discussed novel preclinical data showing a direct anti-tumoral effect of oral treatment with ART26.12. These data are also supportive of Artelo’s planned development of ART26.12 in chemotherapy-induced peripheral neuropathy, where ART26.12 may be able to aid in treatment of the underlying cancer, in addition to the debilitating effects of painful neuropathies. Beyond development for pain and cancer, ART26.12 has also shown the potential for therapeutic activity in dermatologic conditions. FABP5 was first identified in psoriatic lesions and there is evidence to suggest that upregulation of FABP5 contributes to the pathology of psoriasis. Regarding the data in his presentation, “A Novel Fatty Acid-binding Protein 5 Inhibitor Shows Efficacy in Preclinical Models of Psoriasis,” George Warren, Ph.D. commented, “We are pleased to share novel data showing that our lead FABP5 inhibitor, ART26.12, demonstrated compelling data in preclinical models of psoriasis. In this study, ART26.12 reduced the severity of histopathological markers of skin damage and reduced markers of oxidative stress, chemokines, cytokines, and keratinocyte proliferation, and increased antimicrobial peptides. Results were obtained using a standard imiquimod mouse model, which demonstrated ART26.12 had similar levels of activity as Sotyktu (deucravacitinib), an oral tyrosine kinase 2 inhibitor approved by the U.S. Food and Drug Administration in 2022 to treat psoriasis. Sales of Sotyktu may reach $4 billion by the end of the decade, according to Bristol Myers Squibb.” In addition to ART26.12, another one of Artelo’s FABP5 inhibitors was featured in a presentation entitled, “Inhibition of Fatty Acid Binding Protein 5 Prevents Stress-induced Anxiety and Depressive-Like Behavioral Symptoms and Reverses Stress-induced Inhibition of Hippocampal Neurogenesis” where Matthew Jones discussed new results from ongoing studies being conducted at the laboratory of Dr. Steven Laviolette. The data showed that Artelo’s FABP5 inhibitor SBFI103 improved depressive-like behaviors in rats after chronic unpredictable stress, associated with increases in markers of neurogenesis, a critical process in which newly formed neural cells are added to the existing neural network. “This new data supports our laboratory’s earlier work showing SBFI103 reduces anxiety and increased fear memory extinction. These studies implicate a role for the cannabinoid receptor 2 mediating the effects of FABP5 inhibition in the brain,” concluded Jones. “We are pleased to share the expanding evidence for the potential utility of inhibiting FABP5,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo. “These important scientific advances show that lipid modulation is a promising therapeutic strategy across multiple diseases where overactivity of the lipidome contributes to the pathology of the disease or where modulation of the lipidome leads to increased levels of analgesic and anxiolytic lipids. We are grateful for the opportunity to share our data and why we believe development of FABP5 inhibitors from our extensive library could have significant impact for a wide range of diseases. We expect to report on first-in-human trials with ART26.12 next year.” About ART26.12Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN). Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, and anxiety disorders. About the International Cannabinoid Research SocietyThe International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. The ICRS Symposium is being held June 30 – July 5, 2024 in Salamanca, Spain. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information and to view available publications, please visit https://artelobio.com/science/. Forward Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Drug ApprovalClinical Result

01 Jul 2024

·www.drugs.com

Few Patients With Positive Margins After Basal Cell Excision Have Recurrence

MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence, according to a study published online June 13 in Dermatology . Maria Daviti, M.D., from Aristotle University in Thessaloniki, Greece, and colleagues reported the real-life management of incompletely excised BCC in a tertiary referral center and compared recurrence rates according to management modality in a retrospective study. All BCCs with available histopathologic assay reporting at least one involved margin (lateral or deep) over a five-year period were identified. Patients were categorized into three groups: immediate re-excision (group 1; 26 patients); follow-up without any additional treatment (group 2; 40 patients); and treatment with adjuvant/complementary nonsurgical treatment (group 3; 18 patients). The researchers found that based on histopathological reports, 53.8 percent of 26 tumors in group 1 that were re-excised had residual tumor. After a mean follow-up of 17 months, a clinical recurrence occurred in 14 of 84 patients (16.7 percent), with a median of 14 months to recurrence. Recurrence developed in 25 percent of the patients without any additional treatment, compared with 11.1 percent of those receiving nonsurgical treatments. "Our study suggests that positive histopathologic margins after BCC excision result in a clinical recurrence only in a proportion of patients," the authors write. "This percentage is higher when no further treatment is applied and lower when the area is re-excised or treated with imiquimod alone or combined with cryotherapy." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

13 Nov 2023

·www.sciencedaily.com

Researchers develop gel to deliver cancer drugs for solid tumors

Intratumoral therapy -- in which cancer drugs are injected directly into tumors -- is a promising treatment option for solid cancers but has shown limited success in clinical trials due to an inability to precisely deliver the drug and because most immunotherapies quickly dissipate from the site of injection. A team of researchers has developed a gel delivery system that overcomes these challenges. The gel is injectable but solidifies upon delivery; contains an imaging agent for visualization under CT scan; and can hold a high concentration of drug for slow, controlled release. Intratumoral therapy -- in which cancer drugs are injected directly into tumors -- is a promising treatment option for solid cancers but has shown limited success in clinical trials due to an inability to precisely deliver the drug and because most immunotherapies quickly dissipate from the site of injection. A team of researchers from Mass General Brigham, in collaboration with colleagues at the Koch Institute for Integrative Cancer Research, has developed a gel delivery system that overcomes these challenges. The gel is injectable but solidifies upon delivery; contains an imaging agent for visualization under CT scan; and can hold a high concentration of drug for slow, controlled release. In a paper published in Advanced Healthcare Materials, the team reports that using gel-delivered imiquimod (an immune stimulating drug) in combination with checkpoint inhibitor therapy induced tumor regression and increased survival in mouse models of colon and breast cancer that are usually resistant to checkpoint inhibitor therapy. The treatment also appeared to train the immune system to detect and attack distant tumors that were not directly treated, suggesting that it might be a helpful therapy for metastatic cancers. "This gel tackles the two problems with existing attempts at making intratumoral cancer immunotherapy: making the therapy visible and practical so that interventional radiologists can confirm delivery, and making sure the drug actually stays in the region of interest," said Avik Som, MD, PhD, of the Department of Radiology at Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system. "When we inject this gel into a tumor, we're able to teach the immune system to recognize the cancer and trigger it to attack not only the site where the gel was injected, but also other areas in the body where the same cancer may be hiding." The research team, which consisted of both engineers and medical professionals, first developed and optimized the gel-delivery system in the lab by tweaking the gel's chemical structure. One key aspect of the gel's design was that it needed to shift from being liquid at room temperature to make it injectable but become solid at body temperature inside the tumor in order to form a drug-releasing depot, while also retaining drug encapsulation and delivery capability, and carrying sufficient imaging agent. After optimizing the gel in the lab, the team tested its ability to treat mouse models of colon and breast cancer that are usually resistant to immunotherapy. To do this, they used the gel to deliver imiquimod, an FDA-approved immune stimulating drug, in combination with checkpoint inhibitor therapy. Each mouse had two tumors of the same type, but the researchers only treated one tumor per mouse, which allowed them to test the gel's ability to stimulate both local and systemic immunity. They showed that treating with gel-delivered imiquimod in combination with checkpoint inhibitor therapy improved survival in both cancer models. The treatment resulted in an all-or-nothing response -- mice that responded to the treatment showed complete regression of both the treated tumor and a distantly located tumor (a model for metastasis), while non-responders showed no regression at either site. For the colon cancer model, 46% (6/13) survived when the checkpoint inhibitor therapy was combined with gel-delivered imiquimod. For the breast cancer model, 20% (3/15) survived when treated with the combined therapies. "These two tumors remain challenging to treat today, even though immunotherapies are transforming how we think about treatment," said co-corresponding author Giovanni Traverso, MB, PhD, MBBCH, Department of Medicine at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system and an associate professor in the Department of Mechanical Engineering at MIT. "The fact that we were able to induce responses in distant tumors in these colon and breast cancer models was a big win." The researchers are keen to move this technology to the clinic, but it will first need to go through more rounds of testing for safety. They also plan to test its efficacy with a broader panel of drugs. "This is an early proof of concept, but we're all actively working together to try and get these technologies to patients," said Eric Wehrenberg-Klee, MD, assistant radiologist in the Department of Radiology at Massachusetts General Hospital and one of the study's first authors. "There's quite a bit of benefit to be gained by being able to treat patients with a single injection, and we think this technology has the potential to help with cancers that are currently challenging to treat."

ImmunotherapyClinical Result

100 Deals associated with Imiquimod

External Link

KEGG	Wiki	ATC	Drug Bank
D02500	Imiquimod	D06BB10	DB00724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Warts	US	Graceway Pharmaceuticals LLC	24 Mar 2011
Warts	US	Bausch Health US LLC	24 Mar 2011
Basal Cell Carcinoma	US	Bausch Health US LLC	14 Jul 2004
Actinic Keratosis	EU	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	IS	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	LI	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	NO	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	EU	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	IS	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	LI	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	NO	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Condylomata Acuminata	US	Bausch Health US LLC	27 Feb 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cervical Intraepithelial Neoplasia	Phase 3	NL	MEDA Pharma GmbH & Co. KG	01 Dec 2014
Uterine Cervical Dysplasia	Phase 3	NL	MEDA Pharma GmbH & Co. KG	01 Dec 2014
Hutchinson's Melanotic Freckle	Phase 3	FR	MEDA Pharma GmbH & Co. KG	01 Dec 2012
Lentigo maligna melanoma	Phase 3	FR	MEDA Pharma GmbH & Co. KG	01 Dec 2012
Scleroderma, Localized	Phase 3	CA	3M Co.	01 Nov 2005
Carcinoma in Situ	Phase 2	US	Telormedix SA	01 Feb 2013
Carcinoma in situ of bladder	Phase 2	US	Telormedix SA	01 Feb 2013
Non-Muscle Invasive Bladder Neoplasms	Phase 2	US	Telormedix SA	01 Feb 2013
Port-Wine Stain	Phase 2	US	Graceway Pharmaceuticals LLC	01 Oct 2008
Capillary Hemangioma	Phase 2	CA	Graceway Pharmaceuticals LLC	01 Mar 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


phase III clinical study (EADV2023)	Phase 3	Hutchinson's Melanotic Freckle Neoadjuvant	283	Imiquimod	qgevioclwl(nmfrpixmkz) = kyypxcuvms oihuhidexg (dypqfkvoxp ) View more	Positive	11 Oct 2023
phase III clinical study (EADV2023)	Phase 3	Hutchinson's Melanotic Freckle Neoadjuvant	283	Placebo	qgevioclwl(nmfrpixmkz) = wvgvqpyzme oihuhidexg (dypqfkvoxp ) View more	Positive	11 Oct 2023
ESGO2023	Not Applicable	Precancerous Conditions human papillomavirus (HPV) infection	-	Imiquimod 5%	argpmdamzn(gzzcvuubqy) = azbfcisgnu jcuwrlxtve (wughjersdp )	-	27 Sep 2023
ESGO2023	Not Applicable		-	imiquimod	argpmdamzn(gzzcvuubqy) = wfgtpvgafn jcuwrlxtve (wughjersdp )	-	27 Sep 2023
2178 (SGO)	Not Applicable	Vulvar intraepithelial neoplasia	264	Imiquimod	vsyhbupdsp(aolsljtmqt) = lguyzoerxc thvicsfmoi (vdzdxlvolv ) View more	Positive	01 Sep 2023
WCD2023	Not Applicable	Basal Cell Carcinoma \| Actinic Keratosis	66	Topical Imiquimod	yfrsidgbdm(jcuyhvyroq) = jrvowgodap dwbkvommrx (xpryqbzuho ) View more	-	05 Jul 2023
AAD2023	Not Applicable	Actinic Keratosis	17	5-FU 5% and imiquimod 5% creams	wcpeqbjzus(ixloltusrz) = qcktnapuia qfnufvppyq (ekppwjziiv )	-	17 Mar 2023
NCT02135419 (ANCHOR, CTgov)	Phase 3	Human Papillomavirus Infection \| Squamous Intraepithelial Lesions \| HIV Infections ... View more	4,446	infrared photocoagulation therapy+imiquimod+Fluorouracil (Arm I (Treatment))	ubunaakrsv(mayukzwqhu) = cfxzwggoam uuxbujvhhb (kvmwlielrs, khgakfmjkg - lyfbmqyypv) View more	-	02 Dec 2022
NCT02135419 (ANCHOR, CTgov)	Phase 3		4,446	clinical observation (Arm II (Active Monitoring) (Closed Since SEP2021))	ubunaakrsv(mayukzwqhu) = tekoiledkc uuxbujvhhb (kvmwlielrs, ieooyesnux - cqxaguwvsd) View more	-	02 Dec 2022
SITC2022	Not Applicable	Squamous Intraepithelial Lesions M1-like macrophages	35	Imiquimod immunotherapy	jjwfaiaqxp(tsildhodid) = dykgvqzksm medhjpblmm (ciobzzumpp )	Positive	07 Nov 2022
EADV2022	Not Applicable	Skin Neoplasms	191	Imiquimod 5% cream	iugwjrlzco(nbjfyqtpgp) = occur in about half of the patients and followed IMQ administration after the first applications or within the first month of treatment sydhskjwpp (ysqzcuscjv ) View more	-	07 Sep 2022
EADV2022	Not Applicable	Buschke-Lowenstein Tumor human papillomavirus (HPV)	-	Imiquimod 5% cream	bzobsxjjqz(akapruruts) = Complete resolution of the lesions was achieved after 16 weeks dyjlqhtklb (slazbknwcn ) View more	Positive	07 Sep 2022
NCT01861535 (Pubmed \| Lancet)	Phase 3	Vulvar intraepithelial neoplasia	110	Imiquimod	hddnuzuard(fspqhrwbha) = melvnjylzp nhtshloery (yvvrzziaan )	Positive	25 Apr 2022
NCT01861535 (Pubmed \| Lancet)	Phase 3	Vulvar intraepithelial neoplasia	110	imiquimod (Surgery)	hddnuzuard(fspqhrwbha) = bufsbmhekv nhtshloery (yvvrzziaan )	Positive	25 Apr 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis